Literature DB >> 12648604

A case of Müllerian adenosarcoma of the uterus treated with liposomal doxorubicin.

Marcela G del Carmen1, David Lovett, Annekathryn Goodman.   

Abstract

OBJECTIVE: We report on a case of uterine a denosarcoma responsive to treatment with liposomal doxorubicin (Doxil).
METHODS: The clinical course, histopathology, and radiologic studies of the case were reviewed and are reported.
RESULTS: A 69-year-old woman presented to our institution with dehydration and failure to thrive, and recurrent uterine adenosarcoma, 9 months after initial diagnosis. She had undergone total abdominal hysterectomy and bilateral salpingo-oophorectomy at the time of diagnosis, followed by two cycles of Ifosfamide and treatment with megestrol acetate. The patient presented to our institution for hospice care placement, severely dehydrated and with lethargy and with recurrent disease in the pelvis and vagina. She underwent treatment with six cycles of liposomal doxorubicin with a marked response. Given the development of Grade II hand-foot syndrome, liposomal doxorubicin was stopped and two cycles of carboplatin/paclitaxel chemotherapy were administered. Given the patient's disease progression on this regimen, surgical cytoreduction for localized recurrent disease was then performed. The patient developed disease recurrence after a 7-month disease-free interval and 2 years after initial diagnosis. Following another two cycles of liposomal doxorubicin, the patient underwent another cytoreductive procedure for recurrent disease. Two months later, the patient expired, 29 months after diagnosis and 20 months after initial treatment with liposomal doxorubicin chemotherapy.
CONCLUSIONS: Liposomal doxorubicin appears to be active in the treatment of recurrent uterine adenosarcoma.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12648604     DOI: 10.1016/s0090-8258(02)00093-8

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  7 in total

1.  Müllerian adenosarcoma arising from rectal endometriosis.

Authors:  Chunseok Yang; Hoon Kyu Oh; Daedong Kim
Journal:  Ann Coloproctol       Date:  2014-10-28

2.  Clinical benefit of trabectedin in uterine adenosarcoma.

Authors:  Brett A Schroeder; Eve T Rodler; Elizabeth T Loggers; Seth M Pollack; Robin L Jones
Journal:  Med Oncol       Date:  2013-02-28       Impact factor: 3.064

3.  Extragenital Müllerian adenosarcoma with pouch of Douglas location.

Authors:  Tito S Patrelli; Enrico M Silini; Salvatore Gizzo; Roberto Berretta; Laura Franchi; Elena Thai; Adolf Lukanovic; Giovanni B Nardelli; Alberto Bacchi Modena
Journal:  BMC Cancer       Date:  2011-05-15       Impact factor: 4.430

Review 4.  Uterine Adenosarcoma: a Review.

Authors:  Michael J Nathenson; Vinod Ravi; Nicole Fleming; Wei-Lien Wang; Anthony Conley
Journal:  Curr Oncol Rep       Date:  2016-11       Impact factor: 5.075

5.  Extragenital adenosarcoma: a case report, review of the literature, and management discussion.

Authors:  Gloria S Huang; Rebecca C Arend; Antoinette Sakaris; Tiffany M Hebert; Gary L Goldberg
Journal:  Gynecol Oncol       Date:  2009-08-26       Impact factor: 5.482

6.  A Single-Centre Experience on the Management of Adenosarcoma: A Successful Report of an Integrated Medical and Surgical Approach.

Authors:  Myriam Anna Perrone; Margherita Nannini; Giulia Dondi; Donatella Santini; Antonio De Leo; Angelo Paolo Dei Tos; Claudio Zamagni; Maristella Saponara; Lidia Gatto; Concetta Nigro; Paola Bertaccini; Maurizio Zompatori; Pierandrea De Iaco; Anna Myriam Perrone; Maria Abbondanza Pantaleo
Journal:  Clin Med Insights Oncol       Date:  2018-06-18

7.  Treatment of Recurrent or Metastatic Uterine Adenosarcoma.

Authors:  Michael J Nathenson; Anthony P Conley; Heather Lin; Nicole Fleming; Vinod Ravi
Journal:  Sarcoma       Date:  2017-12-28
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.